[Chemotherapy using the CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil) and the VAC protocol (vincristine, adriamycin and cyclophosphamide) in patients with advanced breast cancer].
H
H
Glińska
J
J
Zulichowska
J
J
Radziszewska
M
M
Sukiennik-Siuda
E
E
Trabka
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D014750:Vincristine / Q000008:administration & dosage
D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Chemioterapia według programu CMF (cyklofosfamid, metotreksat, 5-fluorouracyl) i VAC (winkrystyna, adriamycyna, cyklofosfamid) u chorych na zaawansowanego raka sutka.